

CADTH Reference List

Bupropion in Patients With Sexual Dysfunction Associated With Other Antidepressant Therapy

April 2021

Authors: Deba Hafizi, Jennifer Horton

Cite As: *Bupropion in Patients With Sexual Dysfunction Associated With Other Antidepressant Therapy*. Ottawa: CADTH; 2021 Apr. (CADTH reference list: summary of abstracts).

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up to date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca

Key Message

- No relevant evidence-based guidelines were identified regarding adding on or switching to bupropion in patients with sexual dysfunction associated with antidepressant therapy.

Research Question

What are the evidence-based guidelines regarding adding on or switching to bupropion in patients with sexual dysfunction associated with antidepressant therapy?

Methods

Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, Embase, PsycINFO, the Cochrane Database of Systematic Reviews, the international HTA database, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy comprised both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were bupropion and sexual dysfunction. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English-language documents published between January 1, 2011 and April 13, 2021. Internet links were provided, where available.

Selection Criteria and Summary Methods

One reviewer screened literature search results (titles and abstracts) and selected publications according to the inclusion criteria presented in Table 1. Full texts of study publications were not reviewed. The Overall Summary of Findings was based on information available in the abstracts of selected publications. Open-access full-text versions of evidence-based guidelines were reviewed when abstracts were not available and relevant recommendations were summarized.

Results

No relevant references were identified for this report.

References of potential interest that did not meet the inclusion criteria are provided in Appendix 1.

Table 1: Selection Criteria

Criteria	Description
Population	Adults with major depressive disorder, persistent depressive disorder, or treatment-resistant depression, with or without comorbid conditions, experiencing sexual dysfunction associated with antidepressant therapy and who are currently treated with an antidepressant drug (single ingredient or combination) other than bupropion
Intervention	Bupropion, as a single ingredient, as a primary therapy or adjunct to other pharmaceutical therapy, all formulations and all routes of administration
Comparator	Not applicable
Outcomes	Recommendations on adding on or switching to bupropion treatment (e.g., patient characteristics, clinical features, other circumstances)
Study designs	Evidence-based guidelines

Overall Summary of Findings

No relevant literature was found regarding adding on or switching to bupropion in patients with sexual dysfunction associated with antidepressant therapy; therefore, no summary can be provided.

References

Guidelines and Recommendations

No literature identified.

Appendix 1: References of Potential Interest

Clinical Practice Guidelines

Population Unclear

1. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. *Can J Psychiatry*. 2016 Sep;61(9):540-60. [PubMed](#)
See: 3.8. What is the comparative tolerability of second-generation antidepressants?; 3.19. How do you choose between switching to another antidepressant and adding an adjunctive agent? page 553.

Methodology Not Specified

2. The role of medicines in the management of depression in primary care. Dunedin (NZ): bpacnz; 2017: <https://bpac.org.nz/2017/depression.aspx> Accessed 22 Apr 2021.
3. Trangle M, Gursky J, Haight R, et al. Adult Depression in Primary Care. Bloomington (MN): Institute for Clinical Systems Improvement; 2016: <https://www.icsi.org/wp-content/uploads/2019/01/Depr.pdf> Accessed 22 Apr 2021.

Review Articles

4. Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. *Ment Health Clin*. 2016;6(4):191–196. <https://meridian.allenpress.com/mhc/article/6/4/191/128003/Sexual-dysfunction-in-selective-serotonin-reuptake> Accessed 22 Apr 2021. [PubMed](#)
5. Clayton AH, El Haddad S, Iluonakhamhe JP, Ponce Martinez C, Schuck AE. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. *Expert Opin Drug Saf*. 2014 Oct;13(10):1361-1374. [PubMed](#)
6. NIHR Journals Library. Management of sexual dysfunction due to antidepressant medication. 2012; <https://www.journalslibrary.nihr.ac.uk/programmes/hta/1218403/#/documentation> Accessed 22 Apr 2021.
7. Moreira R. The efficacy and tolerability of bupropion in the treatment of major depressive disorder. *Clin Drug Investig*. 2011 Oct 19;31 Suppl 1:5-17. [PubMed](#)